Darovasertib
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research[1][2].
Product Specifications
CAS Number
1874276-76-2
Product Name Alternative
LXS196; IDE196
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PKC
Type
Reference compound
Related Pathways
Epigenetics; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LXS196.html
Purity
99.18
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
NC1=C(C(NC2=C(N3CCC(C)(N)CC3)C=CC=N2)=O)N=C(C4=NC=CC=C4C(F)(F)F)C=N1
Molecular Formula
C22H23F3N8O
Molecular Weight
472.47
Precautions
H302, H315, H319
References & Citations
[1]Protein Kinase C Inhibitor LXS196|[2]US20180179181.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PKCα; PKCθ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TL512019V 500 µL Each
Snapc3 Mouse shRNA Lentiviral Particle (Locus ID 77634)
Sign In for Pricing
View Details 
BNCB1375-100 1x 100 µL
NSE gamma (Neuron Specific Enolase, gamma) (Neuroendocrine Marker) (ENO2/1375), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details